Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study

Autor:	Yasuo Terauchi, Hisataka Fujiwara, Yuji Kurihara, Hideki Suganami, Masahiro Tamura, Masayuki Senda, Ryoji Gunji, Kohei Kaku
Jazyk:	angličtina
Rok vydání:	2019
Předmět:	Glucagon‐like peptide‐1 receptor Sodium–glucose cotransporter 2 inhibitor Type 2 diabetes mellitus Diseases of the endocrine glands. Clinical endocrinology RC648-665
Zdroj:	Journal of Diabetes Investigation, Vol 10, Iss 6, Pp 1518-1526 (2019)
Druh dokumentu:	article
ISSN:	2040-1124 2040-1116
DOI:	10.1111/jdi.13066
Popis:	Abstract Aims/Introduction Tofogliflozin is a potent and highly selective sodium–glucose cotransporter 2 inhibitor that is currently used to treat patients with type 2 diabetes mellitus. The aim of the present study was to evaluate the safety and efficacy of tofogliflozin add‐on to glucagon‐like peptide‐1 (GLP‐1) receptor agonist monotherapy. Materials and Methods In this 52‐week, prospective, multicenter, single arm, post‐marketing clinical study, Japanese patients who had already been receiving GLP‐1 receptor agonist monotherapy for ≥8 weeks, glycated hemoglobin ≥7.0 and
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/5bfd573105c6495d9a9b2340320100d7 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.